Bronkho-Vaksom Vzroslye apply to prevention of recurrent respiratory infections.

Structure

• active ingredient:
• 1 the Bronkho-Vaksom Vzroslye capsule contains the standardized OM-85 lyophilisate containing lyophilisate of bacterial lysates of 7 mg: Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae ssp. pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and sanguinis, Moraxella (Branhamella) catarrhalis;
• other components: the standardized OM-85 lyophilisate: propyl gallate waterless (E 310), sodium glutamate (corresponding to glutamate sodium to anhydrous), mannitol (E 421);
• other components: starch corn prezhelatinizirovanny, magnesium stearate, mannitol (E 421); capsule cover: indigotin (E 132), titanium dioxide (E 171), gelatin.

Side reactions

from the immune system - infrequent: hypersensitivity (rash, urticaria, hypostasis, hypostasis of a century / face, generalized itch, short wind). Frequency is unknown: Quincke's disease.

Disturbance from nervous system – frequent: headache.

Respiratory, thoracic and mediastinal violations – frequent: cough.

from digestive system - frequent: diarrhea, abdominal pain. Infrequently: nausea, vomiting.

from skin and hypodermic cellulose - frequent: rash. Infrequently: an erythema, erythematic rash, generalized rash on skin, an itch.

General violations – infrequent: increased fatigue, peripheral hypostases. Liquid: pyrexia.

At permanent violations from digestive or respiratory system treatment should be stopped.

Contraindication

Hypersensitivity to active ingredient or any of excipients.

Route of administration

Vzroslye and teenagers of 12 years.

Course of preventive treatment: 1 capsule Bronkho-Vaksom. To accept Vzroslye on an empty stomach every day within 10 consecutive days a month 3 months in a row.

at a sharp phase of respiratory infections in combination with other methods of treatment.

Feature of application

Bronkho-Vaksom can cause hypersensitivity reactions. If allergic reactions or signs of intolerance are observed, treatment should be stopped immediately.

Drug contains less than 1 mmol (23 mg) of sodium on the capsule, that is is almost free from sodium.

This the clinical trials showing ability of medicine Bronkho-Vaksom to prevent development of pneumonia, no. Therefore, use of medicine Bronkho-Vaksom for prevention of pneumonia is not recommended.

Use during pregnancy or feeding by a breast

Is not present sufficient researches on animals concerning influence of medicine on pregnancy, embryonic development, fetation and post-natal development. The potential risk for people is unknown. During pregnancy it is recommended to apply with care.

, data are absent. During feeding the breast recommends to apply with care.

Children

to children of 12 years.

Corresponding researches were not conducted by

, but it is improbable that Bronkho-Vaksom will affect ability to steer vehicles and to work with other mechanisms.

to

Interaction with other medicines and other types of interactions

Interaction of medicine with others medicinal and means it is unknown today.

Overdose

About cases of overdose it was not reported.

to Store

at a temperature not above 25 °C. To store out of children's reach.